DERM (Journey Medical) Beginning Cash Position: $24.09 Mil (As of Mar. 2026)


DERM Journey Medical Corp DERM
63 GF Score
Price $7.00
GF Value $4.21
Valuation Significantly Overvalued
! 3 Warning Signs
View Full Analysis

What is Journey Medical Beginning Cash Position?

Journey Medical DERM +5.05% 63 Beginning Cash Position is $24.09 Mil as of Mar. 2026. GuruFocus rates DERM with a GF Score™ of 63/100 and a GF Value™ of $4.21 (Significantly Overvalued). The stock has 3 warning signs investors should review.

Journey Medical's Beginning Cash Position for the quarter that ended in Mar. 2026 was $24.09 Mil.

Journey Medical's quarterly Beginning Cash Position increased from Sep. 2025 ($20.29 Mil) to Dec. 2025 ($24.95 Mil) but then declined from Dec. 2025 ($24.95 Mil) to Mar. 2026 ($24.09 Mil).

Journey Medical's annual Beginning Cash Position declined from Dec. 2023 ($32.00 Mil) to Dec. 2024 ($27.44 Mil) and declined from Dec. 2024 ($27.44 Mil) to Dec. 2025 ($20.31 Mil).

Journey Medical Beginning Cash Position Related Terms

Journey Medical Beginning Cash Position Historical Data

* Premium members only.

The historical data trend for Journey Medical's Beginning Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Journey Medical Beginning Cash Position Chart

Journey Medical Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beginning Cash Position
Get a 7-Day Free Trial 8.25 49.08 32.00 27.44 20.31

Journey Medical Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beginning Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 20.31 21.07 20.29 24.95 24.09
DERM
63GF Score
Journey Medical Corp DERM
Beginning Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Journey Medical Beginning Cash Position Calculation

Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement.

What does a Beginning Cash Position of $24.09 Mil mean?
Journey Medical (DERM) has a Beginning Cash Position of $24.09 Mil as of Mar. 2026. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on Journey Medical and its competitors.
Is Journey Medical's Beginning Cash Position too high?
Journey Medical's current Beginning Cash Position is $24.09 Mil. Overall, Journey Medical has a GF Score™ of 63/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Journey Medical's Beginning Cash Position compare to LFCR and ANIK?
Journey Medical's Beginning Cash Position of $24.09 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beginning Cash Position for a Drug Manufacturers company?
A good Beginning Cash Position depends on the Drug Manufacturers industry context. However, Beginning Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beginning Cash Position mean?
A high Beginning Cash Position can signal that a stock is expensive relative to its fundamentals. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on Journey Medical and its competitors. Journey Medical's current Beginning Cash Position is $24.09 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Journey Medical stock overvalued right now?
Based on GuruFocus' analysis, Journey Medical (DERM) is currently considered Significantly Overvalued. The stock's GF Value™ is $4.21, compared to a current price of $7.00 — trading 66.3% above its estimated fair value. The current Beginning Cash Position is $24.09 Mil. Journey Medical's overall GF Score™ is 63/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beginning Cash Position calculated?
Beginning Cash Position is calculated from a company's financial statements. For Journey Medical (DERM), the current Beginning Cash Position is $24.09 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Journey Medical (DERM) Overvalued in 2026?

Based on GuruFocus' analysis, Journey Medical stock appears to be overvalued. The current stock price of $7.00 is trading 66.3% above its estimated GF Value™ of $4.21. GuruFocus considers Journey Medical to be Significantly Overvalued.

Key valuation signals for DERM:

  • Beginning Cash Position: $24.09 Mil
  • GF Value™: $4.21 vs. price of $7.00 (66.3% above fair value)
  • GF Score™: 63/100 with 3 warning signs

No single metric tells the full story. See the DERM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Journey Medical Business Description

Address 9237 E Via de Ventura Boulevard, Suite 105, Scottsdale, AZ, USA, 85258
Journey Medical Corp is a commercial-stage pharmaceutical company that focuses on the selling and marketing of U.S. Food and Drug Administration (FDA) approved prescription pharmaceutical products for the treatment of dermatological conditions. Its current product portfolio includes FDA-approved prescription drugs for dermatological conditions that are marketed in the U.S. The company views its operations and manages its business in one segment, which reflects products for the treatment of dermatological conditions. The dermatological segment derives revenues from the sale of branded and authorized general prescription products that treat certain dermatological conditions.
63GF Score

Get the complete analysis for DERM

Beginning Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$7.00
Price
$4.21
GF Value